Education
About Us
Working with TipRanks
Follow Us
Compass Therapeutics (CMPX)
NASDAQ:CMPX
CMPX Stock Chart & Stats
$6.16
$0.48(33.57%)
At close: 4:00 PM EST
$6.16
$0.48(33.57%)
Day’s Range― - ―
52-Week Range$1.33 - $6.49
Previous CloseN/A
Volume16.21M
Average Volume (3M)2.20M
Market Cap
$1.10B
Enterprise Value$843.85M
Total Cash (Recent Filing)$219.90M
Total Debt (Recent Filing)$9.87M
Price to Earnings (P/E)―
Beta2.14
Next Earnings
Feb 27, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding177,862,100
10 Day Avg. Volume2,469,140
30 Day Avg. Volume2,195,178
Financial Highlights & Ratios
PEG Ratio-0.44
Price to Book (P/B)1.59
Price to Sales (P/S)233.89
P/FCF Ratio-4.43
Enterprise Value/Market Cap0.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-12.27
Forecast
1Y Price Target
$12.33Price Target Upside100.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Pipeline Activity And DifferentiationConfirmed responses for CTX-8371 in patients previously treated with PD-1 therapy, plus opened expansion cohorts, indicate a differentiated mechanism and increase the likelihood of further clinical progress across multiple tumor types.
Financial Position And Execution CapabilityStrong cash reserves provide a multi-year runway to fund ongoing trials and planned clinical milestones, reducing near-term dilution risk and supporting program execution.
Regulatory Outlook And Market PotentialAnalyst expects Phase 2/3 tovecimig data to demonstrate progression-free and overall survival benefits, supporting regulatory approval prospects and a meaningful US market opportunity in second-line biliary tract cancer.
Bears Say
Combination Safety RiskHigh rates of severe neutropenia and notable discontinuations observed with prior tovecimig plus chemotherapy combinations present a material safety concern that could complicate combination use and regulatory assessment.
Limited Addressable Market In Hodgkin LymphomaSmall patient population that progresses after checkpoint inhibitor therapy in Hodgkin lymphoma limits the commercial opportunity for CTX-8371 in that indication.
Uncertain Benefit Of Checkpoint RechallengeUnclear evidence supporting benefit from rechallenging patients with checkpoint inhibitors creates uncertainty about how broadly CTX-8371 will deliver durable clinical benefit across treated populations.
Compass Therapeutics News
CMPX FAQ
What was Compass Therapeutics’s price range in the past 12 months?
Compass Therapeutics lowest stock price was $1.33 and its highest was $6.49 in the past 12 months.
What is Compass Therapeutics’s market cap?
Compass Therapeutics’s market cap is $1.10B.
When is Compass Therapeutics’s upcoming earnings report date?
Compass Therapeutics’s upcoming earnings report date is Feb 27, 2026 which is in 28 days.
How were Compass Therapeutics’s earnings last quarter?
Compass Therapeutics released its earnings results on Nov 05, 2025. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.139 by $0.059.
Is Compass Therapeutics overvalued?
According to Wall Street analysts Compass Therapeutics’s price is currently Undervalued.
Does Compass Therapeutics pay dividends?
Compass Therapeutics does not currently pay dividends.
What is Compass Therapeutics’s EPS estimate?
Compass Therapeutics’s EPS estimate is -0.1.
How many shares outstanding does Compass Therapeutics have?
Compass Therapeutics has 177,862,100 shares outstanding.
What happened to Compass Therapeutics’s price movement after its last earnings report?
Compass Therapeutics reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.139. Following the earnings report the stock price went up 0.792%.
Which hedge fund is a major shareholder of Compass Therapeutics?
Currently, no hedge funds are holding shares in CMPX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Compass Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.33 (100.22% Upside)
$12.33 (100.22% Upside)
Blogger Sentiment
Bullish
CMPX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 185.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 29.2%
Last 30 Days ▲ 29.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
91.30%
12-Months-Change
Fundamentals
Return on Equity
-37.82%
Trailing 12-Months
Asset Growth
55.05%
Trailing 12-Months
Company Description
Compass Therapeutics
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
CMPX Stock 12 Month Forecast
Average Price Target
$12.33
▲(100.22% Upside)
Technical Analysis
KalVista Pharmaceuticals
―
CytomX Therapeutics
―
Gossamer Bio
―
Bicycle Therapeutics
―
Monopar Therapeutics Inc
―
Ownership Overview
21.45% Insiders
5.93% Mutual Funds
0.02% Other Institutional Investors
64.27% Public Companies and
Individual Investors